NEW YORK, December 25, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD), InterMune Inc. (NASDAQ: ITMN), Tandem Diabetes Care Inc (NASDAQ: TNDM), Nektar Therapeutics (NASDAQ: NKTR), and Greatbatch, Inc. (NYSE: GB). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
ACADIA Pharmaceuticals, Inc. Research Report
On December 20, 2013, ACADIA Pharmaceuticals, Inc.'s (ACADIA Pharmaceuticals) stock went up by 3.47% to close the day at $24.16. For the past three trading days, the Company's stock went up by 5.04%, compared to the Dow Jones Industrial Average which went up by 2.18% during the same three day trading period. The Full Research Report on ACADIA Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/3eb7_ACAD
--
InterMune Inc. Research Report
On December 20, 2013, InterMune Inc.'s (InterMune) stock advanced 4.97%. The Company's stock went up by 4.81% during the past three trading days, compared to the Nasdaq Composite which gained 2.01% during the same three day trading period. The Full Research Report on InterMune Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/dd8c_ITMN
--
Tandem Diabetes Care Inc Research Report
On December 20, 2013, Tandem Diabetes Care Inc (Tandem) announced that the Company was added to the Russell 2000® and Russell 3000® Indexes following reconstitution of Russell Investment Group's family of US indexes, after the market closing on December 20, 2013. Kim Blickenstaff, President and CEO of Tandem, commented, "Being added to the Russell 2000 and Russell 3000 Indexes creates an opportunity to increase our overall visibility among key institutional investors. We believe that added exposure is ultimately beneficial to the company, our shareholders, and our customers." The Full Research Report on Tandem Diabetes Care Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/a1d1_TNDM
--
Nektar Therapeutics Research Report
On December 20, 2013, Nektar Therapeutics' stock went up by 4.00%, closing at $11.19. The Company's stock gained 3.23% during the past three trading days, compared to the Dow Jones Industrial Average, which rose 2.18% during the same trading period. The Full Research Report on Nektar Therapeutics - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/3421_NKTR
--
Greatbatch, Inc. Research Report
On December 20, 2013, Greatbatch, Inc.'s (Greatbatch) stock went up by 3.97%, ending the day at $42.65. Greatbatch's stock rose 6.25% over the past three trading days, compared to the Dow Jones Industrial Average, which gained 2.18% during the same trading period. The Full Research Report on Greatbatch, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/87b5_GB
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
